CEO Kevin Conroy indicated that they were still early in the game trying to figure out what route they go with the FDA on the PanC test. If they choose LDT, that means that this extremely effective and efficient diagnostic (endoscopic procedure) tool could be in the market place sometime in 2017, according to an analyst at Canaccord Genuity in a research note published last Friday.
There was also a note out of Baird today that highlighted a bulk 6500 unit order of CG from a regional clinic in Austin, Tx
Dr. Pardoll was speaking at some kind of Immunology Conference late yesterday and happened to mention Compugen. That's why the stock shot up in the last 20 minutes of trading.
78.4% Specificity is a non-starter.
CCSA-2 is a potential serum-based marker for colon cancer detection with high sensitivity and specificity. Receiver operating characteristic analyses were used to measure the sensitivity and specificity of CCSA-2. CCSA-2 at a cutoff of 10.8 mug/mL has overall specificity of 78.4% [95% confidence interval (95% CI), 67.3-87.1%] and sensitivity of 97.3% (95% CI, 85.8-99.5%) in separating individuals with advanced adenomas and colorectal cancer from normal, hyperplastic, and nonadvanced adenoma populations. The receiver operating characteristic curve for CCSA-2 has an area under the curve of 0.90 (95% CI, 0.83-0.95).
That filing came out on Friday.
It did so because the SEC requires any Fund that goes over 10% ownership to file within 10 days of doing so.
Most Q1 filings will not happen until 45 days from the end of the quarter.
I visited the lab last Summer.
We were told that existing capacity was 1.0 million tests annually, but that they had access to more space in the same office complex that would allow them to ramp up to 2.0 million pretty quickly.
If Colonoscopy is the Gold Standard and such a great procedure for the mass population... then why are 50,000 people dying from CRC every year?